Impact of CMV reactivation on outcomes according to subgroups in multivariate analyses. Forest plots show the adjusted HR of CMV reactivation on relapse (A), nonrelapse mortality (B), and OS (C). Patients with AML and ALL were combined in all analyses. All models were adjusted for recipient age, sex mismatch, CMV serological status, DRI, HCT-CI, donor source, GVHD prophylaxis, conditioning intensity, in vivo T-cell depletion, year of HCT, and grades 2-4 acute GVHD by day 65. In ALL, positivity of Ph-chromosome was also included in the model. Bold indicates statistical significance. DRI, disease risk index; MRD, HLA matched related donors; MUD, HLA matched unrelated donors; MMUD, HLA mismatched unrelated donors.